Key Highlights
- Adjusted EPS of USD 2.11 beat the USD 1.92 estimate, up 11.5% year over year.
- Sales of USD 6.55 billion rose 8.5%, with core sales up 3.0%.
- Core sales excluding respiratory testing grew 5.5%, a 100 basis point step up from Q2.
- Full-year adjusted EPS guidance rose to USD 8.57 to USD 8.62.
Danaher (NYSE:DHR) reported third-quarter results on Wednesday, Oct. 21, with adjusted diluted EPS of USD 2.11, above the USD 1.92 estimate and up 11.5% from a year earlier. Sales were USD 6.554 billion, up 8.5% from USD 6.053 billion and a hair under the USD 6.56 billion estimate, so revenue was essentially in line. GAAP diluted EPS from continuing operations was USD 1.71, which includes a USD 0.37 per share discrete tax benefit.
Danaher is a life sciences and diagnostics company, with Biotechnology, Life Sciences and Diagnostics segments. Shares were up 3.10% at USD 231.18 in Wednesday trading.
Core Sales and Segments
Core sales rose 3.0%, with respiratory testing holding back growth by 2.5 points. Excluding respiratory, core sales grew 5.5%. Acquisitions added 6.5 points to sales, while tariff refunds returned to customers took off 1.0 point.
Biotechnology sales were USD 1,807 million, up 0.5% as reported and 5.0% on a core basis, with bioprocessing orders growing in the mid-teens. Life Sciences sales reached USD 1,865 million, up 4.0%, or 4.5% on a core basis. Diagnostics sales rose 17.0% to USD 2,882 million on the Masimo acquisition, which closed on June 10 for about USD 9.8 billion, while core sales rose 0.5% and 7.0% excluding respiratory. Management put respiratory revenue at about USD 350 million.
Core sales in high-growth markets rose about 10%, led by high-single-digit growth in China, while developed-market core sales were flat.
Margins and Cash Flow
Gross margin was 58.5%, up from 58.2%. The GAAP operating margin was 19.0% versus 19.1%, as a 130 basis point inventory fair-value charge tied to Masimo and the dilutive effect of acquired businesses offset gains from higher core sales and tariff refunds. Management cited an adjusted operating margin of 29.0%, up 110 basis points.
Net earnings from continuing operations were USD 1.207 billion against USD 908 million, helped by the tax benefit and by a year-earlier impairment charge. Interest expense doubled to USD 135 million from USD 67 million on higher borrowing. Free cash flow was USD 1.6 billion for the quarter and USD 4 billion for the first nine months.
Guidance and Leadership
Management raised full-year adjusted EPS guidance to USD 8.57 to USD 8.62 from USD 8.45 to USD 8.60. For the fourth quarter, it guides to core sales growth of 4% to 5% excluding respiratory, a respiratory headwind of about 150 basis points and an adjusted operating margin near 29.5%. The company is planning for USD 1.5 billion of respiratory revenue this year.
Chief Executive Officer Julie Sawyer Montgomery, a few weeks into the role, outlined four priorities: commercial execution, innovation, talent and capital allocation. Management said it closed the StatLab acquisition in early October and described 4% to 5% core growth excluding respiratory as the starting point for 2027.
Items Worth Tracking
Respiratory revenue against the USD 1.5 billion plan is the swing factor management flagged, with flu-season variability worth a couple hundred million dollars either way. Other markers include fourth-quarter core growth against the 4% to 5% guide, bioprocessing order trends, Masimo integration and the margin path toward 29.5%. Academic and government demand was described as improved but still muted.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...